Expect Buzz About Rebyota Fecal Product for C. diff
July 2025
Rebyota will be the first fecal microbiota product marketed in Canada for preventing C. difficile recurrence in adults.
It seems unappealing, but a fecal transplant can help restore a healthy GI flora...or “microbiota.”
Patients have recurrent C. difficile if their symptoms return within 2 to 8 weeks after completing antibiotic treatment...and the risk is increased with certain factors such as recent antibiotic use, age 65 or older, and recent hospital admission.
Get concise advice on drug therapy, plus unlimited access to CE
Pharmacist's Letter Canada includes:
- 12 issues every year, with brief articles about new meds and hot topics
- 200+ CE courses, including the popular CE-in-the-Letter
- Quick reference drug comparison charts
- Access to the entire archive